Core Insights - Polyrizon Ltd. has announced the publication of a national phase patent application by the USPTO, covering its two core platform technologies: Capture and Contain (C&C) and Trap and Target (T&T) [1] Group 1: Company Overview - Polyrizon is a development-stage biotech company focused on innovative intranasal hydrogels, which serve as a barrier against viruses and allergens in the nasal cavity [4] - The C&C platform utilizes a natural 3D polymeric network that adheres to the nasal mucosa, forming a barrier to capture airborne biological threats [2] - The T&T platform is designed for prolonged residence time and effective drug delivery, customizable for various molecules to enhance therapeutic efficacy [3] Group 2: Technology Details - The C&C hydrogel technology acts as a "biological mask," providing a thin shield in the nasal cavity to protect against pathogens [4] - The T&T technology is still in pre-clinical development, focusing on the nasal delivery of active pharmaceutical ingredients (APIs) [4]
Polyrizon Announces Publication of U.S. National Patent Application for Its Innovative Hydrogel Nasal Technologies